申请人:The Du Pont Merck Pharmaceutical Company
公开号:US05356906A1
公开(公告)日:1994-10-18
There is described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.
描述了一种新型(N-邻苯二甲酰亚烷基)哌啶化合物,表现出选择性的σ受体拮抗作用,因此可用于治疗哺乳动物中的生理性或药物诱导的精神病和运动障碍。还描述了含有σ选择性化合物的药物组合物以及使用这些组合物治疗哺乳动物中的生理性或药物诱导的精神病或运动障碍的方法。此外还提供了制备本发明化合物的方法。